Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20


The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.

Hasenoehrl C, Taschler U, Storr M, Schicho R.

Neurogastroenterol Motil. 2016 Dec;28(12):1765-1780. doi: 10.1111/nmo.12931. Epub 2016 Aug 26. Review.


Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Panlilio LV, Justinova Z, Goldberg SR.

Pharmacol Ther. 2013 Apr;138(1):84-102. doi: 10.1016/j.pharmthera.2013.01.003. Epub 2013 Jan 16. Review.


Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.

Harmey D, Griffin PR, Kenny PJ.

Nicotine Tob Res. 2012 Nov;14(11):1300-18. doi: 10.1093/ntr/nts201. Epub 2012 Sep 27. Review.


Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure.

Marusich JA, Wiley JL.

Pharmacol Biochem Behav. 2012 Jun;101(4):575-80. doi: 10.1016/j.pbb.2012.03.004. Epub 2012 Mar 9.


The endocannabinoid system: role in energy regulation.

Gamage TF, Lichtman AH.

Pediatr Blood Cancer. 2012 Jan;58(1):144-8. doi: 10.1002/pbc.23367. Review.


Endocannabinoids and cardiovascular prevention: real progress?

Nodari S, Manerba A, Metra M, Dei Cas L.

Heart Int. 2007;3(1):27. doi: 10.4081/hi.2007.27. Epub 2007 Jun 15.


Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR.

Gastroenterology. 2011 Nov;141(5):1638-47.e1-7. doi: 10.1053/j.gastro.2011.07.036. Epub 2011 Jul 29.


Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior.

Tuesta LM, Fowler CD, Kenny PJ.

Biochem Pharmacol. 2011 Oct 15;82(8):984-95. doi: 10.1016/j.bcp.2011.06.026. Epub 2011 Jun 29. Review.


The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.

Baur R, Gertsch J, Sigel E.

Br J Pharmacol. 2012 Apr;165(8):2479-84. doi: 10.1111/j.1476-5381.2011.01405.x.


Drug addiction.

Justinova Z, Panlilio LV, Goldberg SR.

Curr Top Behav Neurosci. 2009;1:309-46. doi: 10.1007/978-3-540-88955-7_13. Review.


Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Smith TH, Sim-Selley LJ, Selley DE.

Br J Pharmacol. 2010 Jun;160(3):454-66. doi: 10.1111/j.1476-5381.2010.00777.x. Review.


Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism.

Shi Y, Cheng D.

Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E10-8. doi: 10.1152/ajpendo.90949.2008. Epub 2008 Dec 30. Review.


Cannabinoid receptor 1 gene association with nicotine dependence.

Chen X, Williamson VS, An SS, Hettema JM, Aggen SH, Neale MC, Kendler KS.

Arch Gen Psychiatry. 2008 Jul;65(7):816-24. doi: 10.1001/archpsyc.65.7.816.


Endocannabinoid system involvement in brain reward processes related to drug abuse.

Solinas M, Yasar S, Goldberg SR.

Pharmacol Res. 2007 Nov;56(5):393-405. Epub 2007 Sep 8. Review.


The endocannabinoid system as an emerging target of pharmacotherapy.

Pacher P, Bátkai S, Kunos G.

Pharmacol Rev. 2006 Sep;58(3):389-462. Review.


Modulation of P-glycoprotein activity by cannabinoid molecules in HK-2 renal cells.

Nieri P, Romiti N, Adinolfi B, Chicca A, Massarelli I, Chieli E.

Br J Pharmacol. 2006 Jul;148(5):682-7. Epub 2006 May 22.


Harm reduction--the cannabis paradox.

Melamede R.

Harm Reduct J. 2005 Sep 22;2:17.


Supplemental Content

Support Center